NHS England has been cleared to allow prescribing of Almirall’s Ebglyss for some people with atopic dermatitis, giving them the option of a therapy that only needs to be injected once a mon
After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the new indication of atopic dermatitis (AD), a common form of eczema
Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill
Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc
Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh